Waddy SP, et al. - Researchers used the United States Renal Data System and examined patients with end-stage renal disease (ESRD, n=148,294) in order to evaluate mortality and antiseizure medication prescriptions among those with and without a diagnosis of epilepsy. A claims-based definition for epilepsy was met in 13,094 (8.8%) cases. Mortality risk 1.11 times higher was observed among those with epilepsy vs those without, after adjustment for confounders. According to the findings, epilepsy highly prevailed among ESRD patients treated with dialysis and was related to increased mortality risk, in comparison to those without epilepsy. Increased mortality was observed in relation to gabapentin vs other antiseizure medications prescribed to patients with an epilepsy diagnosis. Among dialysis patients with epilepsy, attenuated mortality may be ensured via appropriate multidisciplinary care, treatment, and medication selection.